Healthcare provider profile · identity verified

Scott Thomas Shepherd, D.O.

Allopathic & Osteopathic Physicians|Internal Medicine · TULSA, OK · NPI 1053569640

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Scott Thomas Shepherd, D.O. received $24.20 in general payments during 2025 across 1 reported records.

Pharmacosmos Therapeutics Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$24.20

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Pharmacosmos Therapeutics Inc. Unresolved — no canonical attribution shown $24.20100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$24.201

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
MONOFERRIC
Normalized: monoferric
Drug Pharmacosmos Therapeutics Inc. $24.20 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium287102
Amlodipine BesylateAmlodipine Besylate13552
Levothyroxine SodiumLevothyroxine Sodium13038
GabapentinGabapentin12646
Rosuvastatin CalciumRosuvastatin Calcium12547
LisinoprilLisinopril12050
Losartan PotassiumLosartan Potassium11238
Montelukast SodiumMontelukast Sodium10229
OmeprazoleOmeprazole9430
Metformin HclMetformin Hcl8732
Albuterol Sulfate HfaAlbuterol Sulfate8640
Pantoprazole SodiumPantoprazole Sodium8432
FurosemideFurosemide8329
Trazodone HclTrazodone Hcl8230
Duloxetine HclDuloxetine Hcl7627
Metoprolol SuccinateMetoprolol Succinate7232
HydrochlorothiazideHydrochlorothiazide6327
Tamsulosin HclTamsulosin Hcl6123
CarvedilolCarvedilol6027
SpironolactoneSpironolactone6026
Potassium ChloridePotassium Chloride5925
ClopidogrelClopidogrel Bisulfate5425
Escitalopram OxalateEscitalopram Oxalate5323
Pravastatin SodiumPravastatin Sodium5220
Metoprolol TartrateMetoprolol Tartrate4918
EliquisApixaban4813
MirtazapineMirtazapine4515
Donepezil HclDonepezil Hcl4415
GlimepirideGlimepiride4317
Lantus SolostarInsulin Glargine,hum.Rec.Anlog4318
Sertraline HclSertraline Hcl4117
EzetimibeEzetimibe4013
AzithromycinAzithromycin3722
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide3311
PrednisonePrednisone3228
Buspirone HclBuspirone Hcl3011
Fluoxetine HclFluoxetine Hcl29suppressed
Memantine HclMemantine Hcl29suppressed
Quetiapine FumarateQuetiapine Fumarate29suppressed
Citalopram HbrCitalopram Hydrobromide28suppressed
EstradiolEstradiol2712
Fluticasone PropionateFluticasone Propionate2714
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26suppressed
Ropinirole HclRopinirole Hcl26suppressed
OzempicSemaglutide2412
JardianceEmpagliflozin2311
MeloxicamMeloxicam23suppressed
Cyclobenzaprine HclCyclobenzaprine Hcl22suppressed
Metformin Hcl ErMetformin Hcl2217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22suppressed
AllopurinolAllopurinol21suppressed
MounjaroTirzepatide21suppressed
Olmesartan MedoxomilOlmesartan Medoxomil20suppressed
Diclofenac SodiumDiclofenac Sodium19suppressed
SimvastatinSimvastatin19suppressed
JanuviaSitagliptin Phosphate18suppressed
TopiramateTopiramate18suppressed
Amitriptyline HclAmitriptyline Hcl17suppressed
CephalexinCephalexin1715
Hydroxyzine HclHydroxyzine Hcl17suppressed
Novolog FlexpenInsulin Aspart17suppressed
XareltoRivaroxaban17suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril16suppressed
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16suppressed
Tresiba Flextouch U-100Insulin Degludec16suppressed
Alendronate SodiumAlendronate Sodium15suppressed
SymbicortBudesonide/Formoterol Fumarate15suppressed
Varenicline TartrateVarenicline Tartrate15suppressed
FarxigaDapagliflozin Propanediol14suppressed
Hydralazine HclHydralazine Hcl14suppressed
LantusInsulin Glargine,hum.Rec.Anlog14suppressed
Oxybutynin ChlorideOxybutynin Chloride14suppressed
Breo ElliptaFluticasone/Vilanterol13suppressed
Dropsafe Prep PadsAlcohol Antiseptic Pads13suppressed
Stiolto RespimatTiotropium Br/Olodaterol Hcl13suppressed
TorsemideTorsemide13suppressed
TrulicityDulaglutide13suppressed
Bupropion XlBupropion Hcl12suppressed
CelecoxibCelecoxib12suppressed
Hydroxyzine PamoateHydroxyzine Pamoate12suppressed
Amiodarone HclAmiodarone Hcl11suppressed
AripiprazoleAripiprazole11suppressed
Clonidine HclClonidine Hcl11suppressed
Doxycycline MonohydrateDoxycycline Monohydrate11suppressed
FinasterideFinasteride11suppressed
Isosorbide Mononitrate ErIsosorbide Mononitrate11suppressed
Nifedipine ErNifedipine11suppressed
QuliptaAtogepant11suppressed
Spiriva HandihalerTiotropium Bromide11suppressed
Venlafaxine Hcl ErVenlafaxine Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $24.20 · 1 records Pharmacosmos Therapeutics Inc. MONOFERRIC
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error